J. B. Chemicals & Pharmaceuticals has announced its unaudited standalone and consolidated financial results for Q3 2026 and the nine months ending December 31, 2025. The Board of Directors approved these results, which have been reviewed by the Audit Committee. A limited review of the results was conducted by the statutory auditors. Torrent Pharmaceuticals is set to acquire control over the company pending statutory approvals.
Financial Performance Overview
J. B. Chemicals & Pharmaceuticals has released its unaudited financial results for the quarter and nine months ended December 31, 2025. Key highlights from the standalone results include:
- Revenue from operations for Q3 2026: ₹99,091 lakhs
- Total income for Q3 2026: ₹1,00,780 lakhs
- Net profit after tax for Q3 2026: ₹17,927 lakhs
- Earnings per share for Q3 2026: ₹11.45
For the nine months ended December 31, 2025:
- Revenue from operations: ₹3,05,346 lakhs
- Total income: ₹3,09,850 lakhs
- Net profit after tax: ₹57,756 lakhs
- Earnings per share: ₹37.09
Consolidated Financial Highlights
Key highlights from the consolidated results include:
- Revenue from operations for Q3 2026: ₹1,06,472 lakhs
- Total income for Q3 2026: ₹1,08,300 lakhs
- Net profit after tax for Q3 2026: ₹19,789 lakhs
- Earnings per share for Q3 2026: ₹12.63
For the nine months ended December 31, 2025:
- Revenue from operations: ₹3,24,356 lakhs
- Total income: ₹3,29,173 lakhs
- Net profit after tax: ₹60,810 lakhs
- Earnings per share: ₹38.91
Acquisition by Torrent Pharmaceuticals
Torrent Pharmaceuticals is in the process of acquiring control over J. B. Chemicals & Pharmaceuticals. This acquisition is subject to statutory approvals. The Competition Commission of India (CCI) has approved the acquisition, pending certain modifications. A scheme of amalgamation has been approved, with Torrent issuing shares to J. B. Chemicals shareholders at a pre-agreed swap ratio, pending statutory approvals.
Source: BSE
